Expert Financial Analysis and Reporting

Investment Summary and Thesis In my report of May 31, 2012, I stated that management guidance for Ofirmev sales of $10.0 to $10.5 million for 2Q, 2012 seemed low and I was using a higher estimate of $10.5 million to $11.1 million. Cadence just released market research data on the number of Ofirmev vials shipped […]

Cadence Pharmaceuticals: The Ofirmev Launch is Gaining Traction (CADX, $xx) Investment Thesis I believe that Ofirmev, an intravenous formulation of acetaminophen, has significant potential as an alternative to intravenous opioids and non-steroidal anti-inflammatories analgesics that are used broadly in the hospital. This potential is well illustrated by its launch in the UK where it is […]

I was somewhat alarmed to see a press release entitled “Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection”. Cadence (CADX) is one of the stocks that I am recommending and my experience is that quality control issues can be very messy and disruptive. I wanted to follow-up with management to try […]

Investment Opinion Many or most investors have written off the launch of Ofirmev as either disappointing or an outright failure. I think they are wrong. In its most recent company presentation, Cadence released some unusually detailed figures on the number of Ofirmev vials sold in each month of 2011. These show impressive sequential month over […]

Investment Opinion I believe that the Ofirmev approval is a game changer that can propel Cadence into a successful, medium tier, earnings driven bio-pharmaceutical company. While I am recommending purchase of Cadence, I think that it important for investors to understand the risks and uncertainties of the investment outlook. This note discusses the patent challenge […]

I continue to recommend purchase of Cadence based on trends seen in the 1Q, 2011 period. The details of my recommendation are outlined in my report of March 13, 2011.   Overview and Stock Opinion I believe that Ofirmev meets a major unmet need for an alternative to narcotics and NSAIDs in the intravenous analgesic […]

I am recommending purchase of Cadence Pharmaceuticals based on the promise of its recently launched intravenous analgesic, Ofirmev. Stock Opinion Cadence Pharmaceuticals achieved the dream of every emerging bio-pharmaceutical company when it received US approval for its first product Ofirmev on November 2, 2010; it was then launched on January 17, 2011. Ofirmev is an […]